Analysis of the advantages of peritoneal dialysis in the treatment of chronic refractory heart failure;Análisis de las ventajas de la diálisis peritoneal en el tratamiento de la insuficiencia cardíaca refractaria crónica

Nefrologia

Volumn 30, Issue 5, 2010, Pages 487-489

  Sanchez J E ^a   Rodriguez C ^a   Gonzalez I ^a   Fernandez Vina A ^a   Nunez M ^a   Pelaez B ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; ECONOMICS; EDITORIAL; HEART FAILURE; HOSPITALIZATION; HUMAN; MORTALITY; PERITONEAL DIALYSIS; QUALITY OF LIFE; SPAIN;

COST-BENEFIT ANALYSIS; HEART FAILURE; HOSPITALIZATION; HUMANS; PERITONEAL DIALYSIS; QUALITY OF LIFE; SPAIN;

EID: 78549240265     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2010.Jul.10507     Document Type: Editorial

References (12)

1. Anguita Sánchez M, Crespo Leiro MG, De Teresa Galván E, Jiménez Navarro M, Alonso-Pulpón L, Muñiz García J. Prevalencia de la insuficiencia cardiaca en la población general española mayor de 45 años. Estudio PRICE. Rev Esp Cardiol 2008;61:1041-9.
2. Martínez-Sellés M, García Robles JA, Prieta L, Serrano JA, Muñoz R, Frades E, et al. Annual rates of admission and seasonal variations in hospitalizations for Heart failure. Eur J Heart Fail) 2002; 4:779-86.
3. Rodríguez Artalejo F, Guallar Castillón P, Banegas Banegas JR, Rey Calero J. Trends in hospitalization and mortality for congestive heart failure in Spain, 1980-1993. Eur Heart J 1997;18:1771-9.
4. Cadnapaphornchai MA, Gurevich AK, Weinberger HD, Schrier RW. Pathophysiology of sodium and water retention in heart failure. Cardiology 2001;96:122-31.
5. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopresin. Am J Cardiol 2005;95:8B-13B.
6. Montejo JD, Bajo MA, Del Peso G, Selgas R. Papel de la diálisis peritoneal en el tratamiento de la insuficiencia cardiaca refractaria. Nefrologia 2010;30: 21-7.
7. Sánchez JE, Ortega T, Rodríguez C, Díaz-Molina B, Martín M, García-Cueto C, et al. Efficacy of peritoneal ultrafiltration in the treatment of refractory congestive heart failure. Nephrol Dial Transplant 2010;25:605-10.
8. Krisham A, Oreopulos D. Peritoneal dialysis in congestive heart failure. Advances in Peritoneal Dialysis 2007;23:82-9.
9. Jessup M, Brozena S. Heart failure. NEJM 2003;348:2007-18.
10. Gheorgiade M, Konstam M, Burnett J, et al. Short term clinical effects of tolvaptan, an oral vasopressin antagonist in patients hospitalized for heart failure. The Everest clinical status trials. JAMA 2007;297:1332-43.
11. Kazory A, Ross E. Contemporary trends in the pharmacological and extracorporeal management of heart failure: A Nephrologic perspective. Circulation 2008;117:975-83.
12. Costanzo MR, Guglin M, Saltzberg M, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute descompensated heart failure. J Am Coll Cardiol 2007;49:675-83.